BACKGROUND: The proteasome plays a vital role in the physiology of glioblastoma (GBM), and proteasome inhibition can be used as a strategy for treating GBM. Marizomib is a second-generation, irreversible proteasome inhibitor with a more lipophilic structure that suggests the potential for penetrating the blood-brain barrier. While bortezomib and carfilzomib, the 2 proteasome inhibitors approved for treatment of multiple myeloma, have little activity against malignant gliomas in vivo, marizomib could be a novel therapeutic strategy for primary brain tumors. METHODS: The in-vitro antitumor activity of marizomib was studied in glioma cell lines U-251 and D-54. The ability of marizomib to cross the blood-brain barrier and regulate proteasome activities was evaluated in cynomolgus monkeys and rats. The antitumor effect of marizomib in vivo was tested in an orthotopic xenograft model of human GBM. RESULTS: Marizomib inhibited the proteasome activity, proliferation, and invasion of glioma cells. Meanwhile, free radical production and apoptosis induced by marizomib could be blocked by antioxidant N-acetyl cysteine. In animal studies, marizomib distributed into the brain at 30% of blood levels in rats and significantly inhibited (>30%) baseline chymotrypsin-like proteasome activity in brain tissue of monkeys. Encouragingly, the immunocompromised mice, intracranially implanted with glioma xenografts, survived significantly longer than the control animals (P < .05) when treated with marizomib. CONCLUSIONS: These preclinical studies demonstrated that marizomib can cross the blood-brain barrier and inhibit proteasome activity in rodent and nonhuman primate brain and elicit a significant antitumor effect in a rodent intracranial model of malignant glioma.
BACKGROUND: The proteasome plays a vital role in the physiology of glioblastoma (GBM), and proteasome inhibition can be used as a strategy for treating GBM. Marizomib is a second-generation, irreversible proteasome inhibitor with a more lipophilic structure that suggests the potential for penetrating the blood-brain barrier. While bortezomib and carfilzomib, the 2 proteasome inhibitors approved for treatment of multiple myeloma, have little activity against malignant gliomas in vivo, marizomib could be a novel therapeutic strategy for primary brain tumors. METHODS: The in-vitro antitumor activity of marizomib was studied in glioma cell lines U-251 and D-54. The ability of marizomib to cross the blood-brain barrier and regulate proteasome activities was evaluated in cynomolgus monkeys and rats. The antitumor effect of marizomib in vivo was tested in an orthotopic xenograft model of human GBM. RESULTS:Marizomib inhibited the proteasome activity, proliferation, and invasion of glioma cells. Meanwhile, free radical production and apoptosis induced by marizomib could be blocked by antioxidant N-acetyl cysteine. In animal studies, marizomib distributed into the brain at 30% of blood levels in rats and significantly inhibited (>30%) baseline chymotrypsin-like proteasome activity in brain tissue of monkeys. Encouragingly, the immunocompromised mice, intracranially implanted with glioma xenografts, survived significantly longer than the control animals (P < .05) when treated with marizomib. CONCLUSIONS: These preclinical studies demonstrated that marizomib can cross the blood-brain barrier and inhibit proteasome activity in rodent and nonhuman primate brain and elicit a significant antitumor effect in a rodent intracranial model of malignant glioma.
Authors: Mark J Williamson; Jonathan L Blank; Frank J Bruzzese; Yueying Cao; J Scott Daniels; Lawrence R Dick; Jason Labutti; Anne M Mazzola; Ashok D Patil; Corinne L Reimer; Marjorie S Solomon; Matthew Stirling; Yuan Tian; Christopher A Tsu; Gabriel S Weatherhead; Julie X Zhang; Mark Rolfe Journal: Mol Cancer Ther Date: 2006-12 Impact factor: 6.261
Authors: Richard LeBlanc; Laurence P Catley; Teru Hideshima; Suzanne Lentzsch; Constantine S Mitsiades; Nicholas Mitsiades; Donna Neuberg; Olga Goloubeva; Christine S Pien; Julian Adams; Deepak Gupta; Paul G Richardson; Nikhil C Munshi; Kenneth C Anderson Journal: Cancer Res Date: 2002-09-01 Impact factor: 12.701
Authors: Francesca Pistollato; Hui-Ling Chen; Brian R Rood; Hui-Zhen Zhang; Domenico D'Avella; Luca Denaro; Marina Gardiman; Geertruy te Kronnie; Philip H Schwartz; Elena Favaro; Stefano Indraccolo; Giuseppe Basso; David M Panchision Journal: Stem Cells Date: 2009-01 Impact factor: 6.277
Authors: Erina Vlashi; Kwanghee Kim; Chann Lagadec; Lorenza Della Donna; John Tyson McDonald; Mansoureh Eghbali; James W Sayre; Encrico Stefani; William McBride; Frank Pajonk Journal: J Natl Cancer Inst Date: 2009-02-24 Impact factor: 13.506
Authors: Philip H Schwartz; Peter J Bryant; Tannin J Fuja; Hailing Su; Diane K O'Dowd; Henry Klassen Journal: J Neurosci Res Date: 2003-12-15 Impact factor: 4.164
Authors: Ji Young Yoo; Alena Cristina Jaime-Ramirez; Chelsea Bolyard; Hongsheng Dai; Tejaswini Nallanagulagari; Jeffrey Wojton; Brian S Hurwitz; Theresa Relation; Tae Jin Lee; Michael T Lotze; Jun-Ge Yu; Jianying Zhang; Carlo M Croce; Jianhua Yu; Michael A Caligiuri; Matthew Old; Balveen Kaur Journal: Clin Cancer Res Date: 2016-07-07 Impact factor: 12.531
Authors: G R Tundo; D Sbardella; A M Santoro; A Coletta; F Oddone; G Grasso; D Milardi; P M Lacal; S Marini; R Purrello; G Graziani; M Coletta Journal: Pharmacol Ther Date: 2020-05-19 Impact factor: 12.310
Authors: Grant L Lin; Kelli M Wilson; Michele Ceribelli; Benjamin Z Stanton; Pamelyn J Woo; Sara Kreimer; Elizabeth Y Qin; Xiaohu Zhang; James Lennon; Surya Nagaraja; Patrick J Morris; Michael Quezada; Shawn M Gillespie; Damien Y Duveau; Aleksandra M Michalowski; Paul Shinn; Rajarshi Guha; Marc Ferrer; Carleen Klumpp-Thomas; Sam Michael; Crystal McKnight; Paras Minhas; Zina Itkin; Eric H Raabe; Lu Chen; Reem Ghanem; Anna C Geraghty; Lijun Ni; Katrin I Andreasson; Nicholas A Vitanza; Katherine E Warren; Craig J Thomas; Michelle Monje Journal: Sci Transl Med Date: 2019-11-20 Impact factor: 17.956
Authors: John A DeSisto; Patrick Flannery; Rakeb Lemma; Amrita Pathak; Shelby Mestnik; Natalie Philips; Natalie J Bales; Trinayan Kashyap; Erin Moroze; Sujatha Venkataraman; Andrew L Kung; Bruce D Carter; Yosef Landesman; Rajeev Vibhakar; Adam L Green Journal: Mol Cancer Ther Date: 2019-10-08 Impact factor: 6.261
Authors: Andrew Spencer; Simon Harrison; Jeffrey Zonder; Ashraf Badros; Jacob Laubach; Krystal Bergin; Amit Khot; Todd Zimmerman; Dharminder Chauhan; Nancy Levin; Ann MacLaren; Steven D Reich; Mohit Trikha; Paul Richardson Journal: Br J Haematol Date: 2017-10-26 Impact factor: 6.998
Authors: Esther P Jane; Daniel R Premkumar; Swetha Thambireddy; Brian Golbourn; Sameer Agnihotri; Kelsey C Bertrand; Stephen C Mack; Max I Myers; Ansuman Chattopadhyay; D Lansing Taylor; Mark E Schurdak; Andrew M Stern; Ian F Pollack Journal: Mol Cancer Res Date: 2020-04-01 Impact factor: 5.852